

## Annual General Meeting – Conference Link

PYC Therapeutics (ASX:PYC) (PYC or the Company) reminds shareholders that the Annual General Meeting of the Company (AGM) will be held on Friday 24 November 2023 at 9.00am AWST. The AGM will be held at the Auditorium, The Harry Perkins Institute of Medical Research, QEII Medical Centre, 6 Verdun Street, Nedlands, Western Australia.

**PYC invites all shareholders to join the Company's Annual General Meeting commencing at 9am AWST (12pm AEDST) on Friday 24 November 2023 by registering on the following zoom link:**

Register in advance for this meeting:

[https://us02web.zoom.us/webinar/register/WN\\_6Af4EfZkSa-SVeChWlvdYQ](https://us02web.zoom.us/webinar/register/WN_6Af4EfZkSa-SVeChWlvdYQ)

After registering, you will receive a confirmation email containing information about joining the meeting.

### About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**<sup>1</sup>.

The Company was the first to progress a drug candidate for a blinding eye disease of childhood into human trials and is now progressing multiple 'fast-follower' programs into the clinic. For more information, visit [pyctx.com](https://pyctx.com), or follow us on LinkedIn and Twitter.

### Forward looking statements

*Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes*

<sup>1</sup> Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank <https://doi.org/10.1101/2020.11.02.20222232>

*no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.*

*This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

*This ASX announcement was approved and authorised for release by the CEO of PYC Therapeutics Limited*

## **CONTACTS:**

### **INVESTORS and MEDIA**

[info@pyctx.com](mailto:info@pyctx.com)